Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Piketty

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbancesS Ständer, G Yosipovitch, J-P Lacour, et al.
Antiviral Research|September 7, 2000
The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patientsM Karmochkine, A Si Mohamed, C Piketty, et al.
AIDS (London, England)|November 21, 2002
Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analoguesD Batisse, J P Duong Van Huyen, C Piketty, et al.
The British Journal of Dermatology|October 5, 2021
Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitisJ Puelles, F Fofana, D Rodriguez, et al.
AIDS (London, England)|August 17, 1999
Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapyC Piketty, E Race, P Castiel, et al.
AIDS (London, England)|April 26, 2000
Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenzC Piketty, E Race, P Castiel, et al.
AIDS (London, England)|October 31, 2001
Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patientsA Landau, D Batisse, C Piketty, et al.
AIDS (London, England)|June 6, 2000
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patientsA Landau, D Batisse, J P Duong Van Huyen, et al.
HIV Medicine|April 28, 2007
Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trialJ Ghosn, A-M Quinson, Nd Sabo, et al.
HIV Medicine|June 13, 2002
Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapyL Weiss, M Burgard, Y D Cahen, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Journal of the European Academy of Dermatology and Venereology : JEADV|June 29, 2022
Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbancesS Ständer, G Yosipovitch, J-P Lacour, et al.
Antiviral Research|September 7, 2000
The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patientsM Karmochkine, A Si Mohamed, C Piketty, et al.
AIDS (London, England)|November 21, 2002
Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analoguesD Batisse, J P Duong Van Huyen, C Piketty, et al.
The British Journal of Dermatology|October 5, 2021
Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitisJ Puelles, F Fofana, D Rodriguez, et al.
AIDS (London, England)|August 17, 1999
Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapyC Piketty, E Race, P Castiel, et al.
AIDS (London, England)|April 26, 2000
Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenzC Piketty, E Race, P Castiel, et al.
AIDS (London, England)|October 31, 2001
Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patientsA Landau, D Batisse, C Piketty, et al.
AIDS (London, England)|June 6, 2000
Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patientsA Landau, D Batisse, J P Duong Van Huyen, et al.
HIV Medicine|April 28, 2007
Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trialJ Ghosn, A-M Quinson, Nd Sabo, et al.
HIV Medicine|June 13, 2002
Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapyL Weiss, M Burgard, Y D Cahen, et al.
Pageof 6